News
Shares of Novo Nordisk ( NVO 2.48%) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...
Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.
A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.
WFRV Local 5 on MSN2h
New tariffs could raise prices of Ozempic, Wegovy
Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable ...
Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...
The Score is a weekly review of the biggest stock moves and the news that drove them. Whirlpool expects its performance to spin back around soon. The appliance maker on Monday cut its full-year profit ...
The announcement came amid a slump in the company's share price and investor concerns about its experimental drug pipeline ...
Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the ...
The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback